XML 59 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions and Other Transactions (Unaudited Pro Forma Financial Results) (Details) - Oyster Point Pharma Acquisition - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Business Acquisition [Line Items]    
Business Acquisition, Pro Forma Revenue $ 3,729.1 $ 4,194.4
Business Acquisition, Pro Forma Net Income (Loss) $ 260.5 $ 337.0
Basic (in usd per share) $ 220,000 $ 280,000
Diluted (in usd per share) $ 220,000 $ 280,000
Basic (in shares) 1,202,500 1,210,500
Diluted (in shares) 1,205,600 1,213,100